Literature DB >> 21273626

Parameters of biological activity in colorectal cancer.

Sarka Svobodova1, Ondrej Topolcan, Lubos Holubec, Miroslav Levy, Ladislav Pecen, Stepan Svacina.   

Abstract

BACKGROUND: The aim of this study was to measure several parameters in patients with early-stage colorectal cancer (CRC) and to evaluate them for their utility in routine clinical practice. PATIENTS AND METHODS: Pre-operative serum levels of the following parameters were measured in 174 patients with CRC (clinical stage I-III): carcinoembryonic antigen (CEA), carbohydrate antigen CA 19-9, proliferative marker thymidine kinase (TK), tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS), interleukin-6 (IL-6), interleukin-10 (IL-10), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), vascular endothelial growth factor (VEGF), C-peptide, insulin, adiponectin and leptin. The control group consisted of 50 patients who were undergoing a complete preventive medical examination and in these patients at the time of blood collection there was no evidence of any cancer disease.
RESULTS: Significant increase of the following parameters was found in patients with CRC: CEA, CA 19-9, TPA, IL-6, IL-10, TIMP-1, C-peptide, insulin and adiponectin. Only two of these, CA 19-9 and adiponectin, represent highly unfavorable prognostic factors. If elevated, they affect both progression-free interval and overall survival.
CONCLUSION: Based on our results, we can conclude that none of the measured parameters fulfills the criteria for use for screening nor for primary diagnosis of CRC. Some of the parameters are important for prognosis estimate: Elevated CA 19-9 is related to an unfavorable prognosis, in terms of cancer recurrence and mortality rate. Angiogenetic factor VEGF represents a prognostic factor important for OS. CEA represents a parameter which is related to disease progression. Interleukins seem to be prospective complementary tumor markers. Adiponectin may be used for estimation of advanced stage of cancer and for estimate of risk of cancer recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273626

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk.

Authors:  Mathilde Touvier; Léopold Fezeu; Namanjeet Ahluwalia; Chantal Julia; Nathalie Charnaux; Angela Sutton; Caroline Méjean; Paule Latino-Martel; Serge Hercberg; Pilar Galan; Sébastien Czernichow
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

2.  Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.

Authors:  Xue-Qin Yang; Chuang Chen; Chun-Wei Peng; Shao-Ping Liu; Yan Li
Journal:  Med Oncol       Date:  2011-05-07       Impact factor: 3.064

3.  Ribosomal protein S27-like in colorectal cancer: a candidate for predicting prognoses.

Authors:  Chi-Jung Huang; Shung-Haur Yang; Chia-Long Lee; Yu-Che Cheng; Szu-Yun Tai; Chih-Cheng Chien
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

4.  Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma.

Authors:  Lichao Sun; Chunguang Guo; Joseph Burnett; Zhihua Yang; Yuliang Ran; Duxin Sun
Journal:  Oncotarget       Date:  2016-11-29

Review 5.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Authors:  Bodo E Lippitz; Robert A Harris
Journal:  Oncoimmunology       Date:  2016-05-11       Impact factor: 8.110

6.  TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis.

Authors:  Chunyan Meng; Xiaowei Yin; Jingting Liu; Kaifeng Tang; Hongchao Tang; Jianhua Liao
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

Review 7.  Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.

Authors:  Noomi Vainer; Christian Dehlendorff; Julia S Johansen
Journal:  Oncotarget       Date:  2018-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.